Table 1 Some examples of targeted therapies for cancer
From: Biology-driven cancer drug development: back to the future
Drug | Brand name | Drug target* | Cancer types |
|---|---|---|---|
In clinical use | |||
   Bevacizumab | Avastin | VEGF | Colorectal, non-small cell lung, breast, renal |
   Bortezomib | Velcade | Proteasome | Myeloma, lymphoma |
   Celecoxib | Onsenal | COX2 | Familial adenomatous polyposis |
   Erlotinib | Tarceva |  |  |
   Gefitinib | Iressa | EGFR | Non-small cell, lung, colorectal, head and neck |
   Cetuximab | Erbitux |  |  |
   Panitumumab | Vectibix |  |  |
   Imatinib | Gleevec |  |  |
   Dasatinib | Sprycel | BCR-ABL, cKIT, PDGFR | Leukemia, gastrointestinal |
   Nilotinib | Tasigna |  |  |
   Methotrexate |  | DHFR | Multiple cancer types |
   RAD001 | Certican | mTOR | Renal |
   Temirolimus | Toricel |  |  |
   Sorafenib | Nexavar | VEGFR, RAF, cKIT, PDGFR | Renal, hepatic |
   Sunitinib | Sutent |  |  |
   Topotecan | Hycamtin | Topoisomerase I | Multiple cancer types |
   Irinotecan | Camptosar |  |  |
   Trastuzumab | Herceptin | ERBB2 | Breast |
   Lapatinib | Tykerb | HER2, EGFR | Breast |
   Tamoxifen | Nolvadex | ERα | Breast |
   Exemestane | Aromasin |  |  |
   Anastrozole | Arimidex | Aromatase cytochrome P450 | Breast |
   Letrozole | Femara |  |  |
   Rituximab | MabThera | CD20 | Lymphoma |
   Tositumomab | Bexxar |  |  |
In development | |||
   17AAG |  | HSP90 |  |
   ABT-737, ABT-263, Obatoclax |  | BCL-XL, BCL-2 |  |
   Alvocidib |  | CDKs |  |
   Olaparib, AG014699 |  | PARP1/2 |  |
   BEZ235 |  | PI3K |  |
   GRN163L |  | hTERT |  |
   Mapatumumab |  | TRAIL Receptor |  |
   Nutlin-3 |  | MDM2 |  |
   PLX4032 |  | BRAF |  |
   GDC-0449 |  | SMO |  |
   PF-0477736 |  | CHK1 |  |